Regencell Bioscience Holdings LtdRGC

Regencell Bioscience Holdings Ltd does not sell a product you can buy today, and its latest 20-F filing (period ending 30 June 2025) confirms the gap between the polished brochures and the cash ledger. The company reports a net loss of $3.6 million, an operating loss of $3.8 million, and a diluted loss per share of $0.72 on 494.5 million weighted average diluted shares. Assets of $5.8 million include $2.5 million of short-term investments, while operating cash burn was $3.1 million for the period. The balance sheet shows equity of $4.9 million, but the business is still waiting for revenues to arrive in any disclosed amount.

Regencell describes itself in SEC filings as a company focused on the development and commercialisation of its RGC-COV19™ liquid-formula therapy, an investigational treatment for mild to moderate COVID-19 symptoms. The company’s 6-K (19 May 2026) announces a registered direct offering and a definitive partnership agreement under which Regencell is required to donate 3.0% of net revenue once revenue exists. The product’s efficacy was the subject of earlier press releases touting additional EARTH efficacy trial results, but no revenue, approval, or commercial launch date appears in the latest filings.

Regencell’s SEC filings for the year to 30 June 2025 show: net loss attributable to parent $-3.6M; operating loss $-3.8M; diluted EPS $-0.72; weighted average diluted shares 494.5M; assets $5.8M (including $2.5M short-term investments); liabilities $895,308; equity $4.9M; net cash used in operating activities $-3.1M; capex $152,689; R&D expense $948,289. The company’s 20-F and related exhibits are available via the SEC EDGAR index for CIK 1829667.

The company has used multiple SEC filings in the past two months to raise capital: a registered direct offering (6-K, 19 May 2026), an at-the-market offering programme (6-K, 30 Mar 2026), and a 424B5 shelf registration (19 May 2026). Each filing is a capital-raising success and an operating-reality vacuum, with no revenue disclosures, no guidance, and no commercial milestones attached to the cash raised.

Regencell’s investor-relations page lists press releases including ‘Regencell Bioscience Announces Additional EARTH Efficacy Trial Results Corroborating Effectiveness of its Investigational Liquid-Formula RGC-COV19™ in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-Day Treatment Period,’ but the latest filings do not disclose any sales, contracts, or regulatory approvals. The product image on the company’s website shows a dropper bottle labelled RGC-02, but the image proves nothing about efficacy, revenue, or commercial readiness. The absence of revenue and the presence of repeated equity issuance together describe a company whose primary product remains an aspiration rather than an asset.

If you are looking for chart context, the company trades on the Singapore Exchange under the ticker 43D.SI. The company’s filings do not provide revenue or volume data that would support technical analysis, so any chart commentary beyond the statutory ticker route is outside the evidence set provided.